Rafael Fonseca: Some musings on myeloma therapy after coming back from ASCO and EHA 2023.

Gustavo Nader Marta: CDK inhibitors applied sequentially and after RT postoperative showed a low profile of acute toxicity and suit- able oncological outcomes.

David Sebag-Montefiore: PROSPECT compared chemotherapy with chemoradiation. There was greater acute toxicity with pre-op chemotherapy.

Vivek Subbiah: Lurbinectedin was approved for Small cell Lung in USA and now is also approved in Canada, Australia, Singapore, the United Arab Emirates, Qatar, South Korea, Ecuador, Mexico, Israel and Switzerland.

Naveen Pemmaraju: New paper alert from our group led by our doctor Montalban Bravo and professor Garcia Manero.

Antonio Marra: In an analysis of more than 28k pts, pancreatic acinar cell carcinoma was the cancer type with the highest prevalence of gBRCA2 and HRD features.

Vivek Subbiah: The 3rd KRAS G12C kid on the block.

Todd Harper: E-cigarette usage is the biggest predictor of people taking up smoking, according to new Cancer Council Victoria research

Anirban Maitra: The phase 1 data of Genentech’s KRAS G12C inhibitor Divarasib was published yesterday in NEJM.

Shernan Holtan: More evidence of an unfriendly role of amphiregulin.